ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,967Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 99

$1.15M Total Retail Price of All Prescriptions

Rank: 3 out of 99

653 Patients Receiving at Least One Drug in Part D
69%Patients 65 Years and Older
50% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Virginia
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

3% of this provider’s 653 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

3% of this provider’s 8,476 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

39% of this provider’s prescriptions were for brand-name drugs, compared to an average of 46%.

Prescription Price

$96 was the average price of a prescription from this provider, compared to $137 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Virginia
LEVOTHYROXINE SODIUM 714 541 1 1
METFORMIN HCL 559 380 2 3
AMLODIPINE BESYLATE 422 267 3 14
LANTUS 401 274 4 7
SYNTHROID 393 299 5 2
METHIMAZOLE 374 318 10 6 16
HUMALOG 361 194 7 10
INSULIN SYRINGE 329 208 8 9
SIMVASTATIN 327 278 9 8
NOVOLOG 312 223 10 18
GABAPENTIN 300 194 11 21
PEN NEEDLE 275 169 12 4
CRESTOR 255 184 13 27
NOVOLOG FLEXPEN 238 127 14 17
GLIMEPIRIDE 231 188 15 6
RAMIPRIL 212 176 16 48
ATORVASTATIN CALCIUM 202 183 17 15
DIOVAN 195 135 18 62
LANTUS SOLOSTAR 193 110 19 5
ALENDRONATE SODIUM 177 149 20 35
AMITRIPTYLINE HCL 176 110 R 21 58
NATEGLINIDE 174 156 22 46
OMEPRAZOLE 171 105 23 37
LEVEMIR 161 123 24 33
JANUVIA 147 103 25 13
LEVEMIR FLEXPEN 142 66 26 24
ENALAPRIL MALEATE 140 99 27 68
LOSARTAN POTASSIUM 135 124 28 20
GLYBURIDE-METFORMIN HCL 129 108 R 29 70
FUROSEMIDE 123 113 30 32
GEMFIBROZIL 119 65 31 73
LISINOPRIL 112 84 32 11
PANTOPRAZOLE SODIUM 106 65 33 77
HYDROCHLOROTHIAZIDE 106 56 33 26
POTASSIUM CHLORIDE 103 93 35 36
METOPROLOL TARTRATE 103 74 35 51
ZETIA 96 67 37 55
BENAZEPRIL HCL 95 25 38 80
KLOR-CON M20 94 81 39 65
ATENOLOL 94 68 39 42
METOPROLOL SUCCINATE 89 66 41 44
GLIPIZIDE 83 77 42 22
ALLOPURINOL 77 65 43 84
JANUMET 72 61 44 28
ZOLPIDEM TARTRATE 66 26 45 54
ACTONEL 66 43 45 91
FENOFIBRATE 57 48 47 41
ACTOS 54 44 48 43
CITALOPRAM HBR 52 37 49 101
TRICOR 52 30 49 101
NEXIUM 51 19 51 78
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 14, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.